Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3933732 | 1.00 | TBXAS1 (0.33) | TBXAS1CYP24A1MEN1LMNAMAPK1 | |
| SCHEMBL4616981 | 0.99 | TBXAS1 (0.34) | TBXAS1CYP24A1MEN1LMNAMAPK1 | |
| SCHEMBL4616984 | 0.99 | TBXAS1 (0.34) | TBXAS1CYP24A1MEN1LMNAMAPK1 | |
| Bromide SCHEMBL3930965 | 0.85 | MEN1 (0.36) | TBXAS1MEN1LMNAMAPK1KMT2A | |
| Bromide SCHEMBL3930970 | 0.85 | MEN1 (0.36) | TBXAS1MEN1LMNAMAPK1KMT2A | |
| Bromide SCHEMBL3937837 | 0.85 | CYP24A1 (0.33) | TBXAS1CYP24A1MEN1LMNAMAPK1 | |
| Bromide SCHEMBL3936424 | 0.85 | TBXAS1 (0.36) | TBXAS1MEN1LMNAMAPK1KMT2A | |
| Bromide SCHEMBL3936422 | 0.85 | TBXAS1 (0.36) | TBXAS1MEN1LMNAMAPK1KMT2A | |
| SCHEMBL4602891 | 0.84 | MEN1 (0.36) | TBXAS1MEN1LMNAMAPK1KMT2A | |
| SCHEMBL4602896 | 0.84 | MEN1 (0.36) | TBXAS1MEN1LMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569079-B2 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | KRT18, CKMT1A; CKMT1B, XRCC5 | TBXAS1 4801/4885CYP24A1 3227/4885MEN1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.